Menu Search

BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)46.15
  • Today's Change0.50 / 1.10%
  • Shares traded87.68k
  • 1 Year change+27.84%
  • Beta0.9439
Data delayed at least 15 minutes, as of Mar 04 2026 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CHFView more

In 2025, BB Biotech AG increased its cash reserves by 21,344.54%, or 97.76m. The company earned 309.14m from its operations for a Cash Flow Margin of 50.13%. In addition the company used on investing activities and also paid 203.20m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share50.39
Tangible book value per share50.39
More ▼

Balance sheet in CHFView more

BB Biotech AG has little financial risk as the capital structure does not rely on leverage.
Current ratio399.45
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in CHF

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 661.52%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)4.99%
Div growth rate (5 year)-8.97%
Payout ratio (TTM)21.56%
EPS growth(5 years)-3.32
EPS (TTM) vs
TTM 1 year ago		666.44
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.